Daiichi's Lixiana nabs backing from NICE; Recipharm gets financing; GSK, Novartis India plans win watchdog approval;

@FiercePharma: Did squirrels pass a killer virus to people? FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: Which companies had highest comped CEOs? Hint, most are U.S. and did not necessarily make the most money. Special report | Follow @EricPFierce

@CarlyHFierce: I triple-dog-dare someone to make this new creepy-as-hell $GSK vaccine ad their Twitter pic. Story | Follow @CarlyHFierce

> The cost-effectiveness watchdogs at the National Institute for Health and Care Excellence (NICE) backed Daiichi Sankyo's new warfarin-alternative anticoagulant Lixiana to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE). Release

> Recipharm sewed up new bank financing to finance its growth plans from DNB, Handelsbanken and Swedbank. Report

> Indian regulators cleared a variety of pharma's foreign investment proposals for the country, including those from GlaxoSmithKline ($GSK), Novartis ($NVS) and Mylan ($MYL). Report

> The Obama administration issued new rules allowing closely held companies such as Hobby Lobby to opt out of covering contraceptives if they have religious objections. Report

> The Scottish Medicines Consortium blessed the use of Bayer's Nexavar to treat thyroid cancer, a new use for the drug. Report

> India's Dr. Reddy's Laboratories ($RDY) launched its version of Allergan's ($AGN) Alzheimer's pill Namenda in the U.S. Report

Medical Device News

@FierceMedDev: ICYMI: Magic material: graphene protects chemotherapy, but silver-lined catheters break it down. Article | Follow @FierceMedDev

@StacyALawrence: Aum Cardio raises $5M to back hand-held, in-office CAD Dx device. Article | Follow @StacyALawrence

@EmilyWFierce: The experience of having your blood drawn by Theranos, as laid out by @danmunro. More | Follow @EmilyWFierce

> German prosthetics company mulls IPO for 2017. Story

> U.S. House passes provision to keep tabs on medical devices used on patients. Article

Biotech News

@FierceBiotech: Roche hustles to FDA with PhII PD-L1 cancer success for 'breakthrough' star atezolizumab. News | Follow @FierceBiotech

@JohnCFierce: You want to see why execs are leaving Big Pharma for biotech? It's where the money is. Report | Follow @JohnCFierce

@DamianFierce: Actual line: "Sorrento recently entered into a definitive agreement with NantPharma to acquire the rights for Cynviloq™ from Sorrento." | Follow @DamianFierce

> As schizophrenia rivals rush in, Otsuka and Lundbeck gain FDA OK for Rexulti. News

> Anacor soars as its eczema cream succeeds in Phase III. Article

Animal Health News

> FDA cracks down on Vegas firm selling unapproved kidney drug for dogs and cats. Article

> Perdue ditches all antibiotics for new chicken line, General Mills goes cage-free. Report

> Did squirrels pass a killer virus to people? More

> Senate committee, USDA, poultry producers meet to discuss deadly U.S. avian flu outbreak. Story

> Sweden's Oasmia regains rights to cancer drugs from Zoetis, files for $23M IPO. Article

Biotech IT News

> 21st Century Cures Act clears House with data sharing, standardization sections intact. Story

> Genomics vs YouTube: Which will have the greater computing requirements in 2025? More

> GSK working to build Apple's ResearchKit into its clinical trials. Report

> Financially motivated hackers break into 3 major pharma companies in 18 months. Article

> Core Informatics snags $17.5M to fuel lab software land grab. Story

Pharma Marketing News

> Novartis off to scorching start with Copaxone generic Glatopa. Article

> Novo Nordisk looks past blockbuster Victoza with PhIII success for weekly GLP-1 med. Item

> For Entresto rollout, Novartis marketing mixes tried-and-true with new-and-different. Story

> How does the Keytruda-Opdivo marketing battle stack up? More

> GSK's big, bad whooping cough vaccination campaign bares its teeth. Article

And Finally... Walgreen's ($WBA) tapped interim CEO Stefano Pessina to stick around in the top job. Report

Suggested Articles

Amid a tough fight in the blood thinner market, J&J and Bayer's Xarelto scored a trial win in treating PAD patients after a recent leg artery surgery.

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.

Bluebird said it doesn't expect to complete a U.S. application for the gene therapy until mid-2021 amid COVID-19 and a lack of agreement with the FDA.